Skip to main content
. 2022 Nov 13;114(2):654–664. doi: 10.1111/cas.15617

FIGURE 4.

FIGURE 4

Antitumor activity of TAS2940 in multiple mouse xenograft models harboring several human epidermal growth factor receptor type 2 (HER2)/epidermal growth factor receptor (EGFR) aberrations. TAS2940, poziotinib, or vehicle was given orally once daily for 14 days in subcutaneous xenograft models bearing (A) NCI‐N87, (B) MCF10A_HER2/insYVMA_v, or (C) NSCLC NCI‐H1975 EGFR D770_N771insSVD. (D) TAS2940, afatinib, osimertinib, or vehicle was given orally once daily for 11 days in subcutaneous xenograft models bearing glioblastoma PDX35. Data are shown as the mean ± SE (n = 6 in A–C; n = 5 in D).